Oncology Drugs - Estonia

  • Estonia
  • The Oncology Drugs market in Estonia is estimated to achieve a revenue of US$50.53m in 2025.
  • It is anticipated that the revenue will experience an annual growth rate (CAGR 2025-2029) of 6.70%, leading to a market volume of US$65.49m by 2029.
  • When compared globally, United States is expected to generate the highest revenue of US$111,500.00m in 2025.
  • Estonia's oncology drug market is witnessing a surge in innovative therapies, propelled by the country's commitment to digital health advancements.

Key regions: France, Europe, United Kingdom, Brazil, India

Market
Region
Region comparison
Currency

Revenue

Please wait

Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

Most recent update: Jun 2024

Source: Statista Market Insights

in billion USD (US$)

Please wait

Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

Most recent update: Mar 2024

Please wait

Most recent update: Mar 2024

Source: Statista Market Insights

Health

Access more Market Insights on health topics with our featured report

This report presents a comprehensive analysis and additional information on the Oncology Drugs market, in a PDF format.
Oncology Drugs: market data & analysis - Background Oncology Drugs: market data & analysis - Cover

Analyst Opinion

The demand for oncology drugs in Estonia has been steadily increasing over the years.

Customer preferences:
Estonia has a high incidence of cancer, which has led to an increased demand for oncology drugs. Patients are increasingly seeking personalized treatments that are tailored to their specific needs. This has led to a growing demand for targeted therapies, which are designed to attack cancer cells while minimizing damage to healthy cells. Patients are also looking for treatments that have fewer side effects and are more affordable.

Trends in the market:
The oncology drugs market in Estonia is expected to grow in the coming years due to the increasing incidence of cancer and the growing demand for targeted therapies. The market is also being driven by the introduction of new drugs and the expansion of existing drug portfolios. The trend towards personalized medicine is also expected to continue, with more patients seeking treatments that are tailored to their specific needs.

Local special circumstances:
Estonia has a well-developed healthcare system that provides universal access to healthcare for all citizens. The country has a high standard of living, which has led to a growing demand for high-quality healthcare services. The government has also been investing in the healthcare sector, which has helped to drive growth in the oncology drugs market.

Underlying macroeconomic factors:
Estonia has a stable economy and a favorable business environment, which has attracted investment from multinational pharmaceutical companies. The country has a highly educated workforce and a strong research and development sector, which has helped to drive innovation in the healthcare sector. The government has also implemented policies to promote the growth of the pharmaceutical industry, including tax incentives and funding for research and development. These factors have helped to create a favorable environment for the growth of the oncology drugs market in Estonia.

Next generation therapy

Please wait

Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

Most recent update: Sep 2024

Source: Statista Market Insights

Key Players

in percent

2023
Please wait

Most recent update: Dec 2024

Source: Statista Market Insights

Global Comparison

Please wait

Most recent update: Jun 2024

Source: Statista Market Insights

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Key Market Indicators

The following Key Market Indicators give an overview of the social and economic outlook of the selected region and provide additional insights into relevant market-specific developments. These indicators, together with data from statistical offices, trade associations and companies serve as the foundation for the Statista market models.

Please wait

Source: Please wait

Explore more high-quality data on related topic

Discover additional markets

Explore new markets and gain valuable insights into various topics with our Market Insights search function.

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)